Lörrach, Germany

Jürgen Geiwiz


Average Co-Inventor Count = 2.9

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Lorrach, DE (1997)
  • Lörrach, DE (2008)

Company Filing History:


Years Active: 1997-2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jürgen Geiwiz: Innovator in Azo Dyestuffs and DNA Gyrase Inhibitors

Introduction

Jürgen Geiwiz is a notable inventor based in Lörrach, Germany. He has made significant contributions to the fields of chemistry and pharmaceuticals, particularly through his innovative patents. With a total of 2 patents, Geiwiz has focused on developing compounds that have practical applications in various industries.

Latest Patents

Geiwiz's latest patents include advancements in azo dyestuffs and DNA gyrase inhibitors. The first patent pertains to azo dyestuffs, specifically compounds of formula (I) wherein all substituents have the meanings as defined in the specification, their production, and their use. The second patent involves mono- and bicyclic DNA gyrase inhibitors, which relate to a compound of a specific formula that inhibits DNA gyrase activity in bacteria. This compound possesses antibiotic properties, particularly against microorganisms, and can be utilized in the control or prevention of infectious diseases.

Career Highlights

Throughout his career, Jürgen Geiwiz has worked with prominent companies such as Clariant Finance Limited and Hoffmann-La Roche Inc. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in his field.

Collaborations

Geiwiz has collaborated with notable colleagues, including Martin Oberholzer and Erwin Gotschi. These partnerships have likely enhanced his research and development efforts, leading to innovative solutions in his areas of expertise.

Conclusion

Jürgen Geiwiz is a distinguished inventor whose work in azo dyestuffs and DNA gyrase inhibitors has made a meaningful impact in the scientific community. His patents reflect his commitment to innovation and the advancement of technology in pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…